Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reasonable-zone remains at 15% in Japan

This article was originally published in Clinica

Executive Summary

Japan's "reasonable zone" for discounting Special Treatment Materials prices is to remain at 15%, under the revised reimbursement scheme effective this month. However, industry has had "no firm commitment from the Japanese government that the R-zone will stay at 15%" when the next round of reimbursement revisions takes place in 1998, US industry association HIMA told Clinica. As Clinica went to press, HIMA was testifying on Capitol Hill to a Ways and Means Committee on trade with Japan. The R-zone was one of the main issues under discussion.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel